FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/10/075620 [Registered on: 22/10/2024] Trial Registered Prospectively
Last Modified On: 21/10/2024
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Drug
Surgical/Anesthesia 
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   to compare the time duration of pain relief by adding injection dexmedetomidine and injection butorphanol in erector spinae plane block in children 1 year to 18 years posted for chest and abdominal surgeries  
Scientific Title of Study   A comparative study of dexmedetomidine and butorphanol as an adjuvant in ultrasound-guided erector spinae plane block for perioperative analgesia in children undergoing thoracoabdominal surgeries 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Shambhavi Sharma 
Designation  Senior resident 
Affiliation  Postgraduate Institute of Child Health  
Address  Department of paediatric anaesthesias second floor, postgraduate institute of child health, Sector 30, Noida, Uttar pradesh

Gautam Buddha Nagar
UTTAR PRADESH
201301
India 
Phone  9606322036  
Fax    
Email  drshambhavi2020@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Mukul Jain 
Designation  Professor and head of department 
Affiliation  POSTGRADUATE INSTITUTE OF CHILD HEALTH 
Address  Department of paediatric anaesthesia, Second floor, Postgraduate institute of child health, Sector 30, Noida, Uttar pradesh

Gautam Buddha Nagar
UTTAR PRADESH
201301
India 
Phone  9971588623  
Fax    
Email  jainmukul2004@yahoo.com  
 
Details of Contact Person
Public Query
 
Name  Dr Mukul Jain 
Designation  Professor and Head of department  
Affiliation  Postgraduate Institute of Child Health  
Address  Department of paediatric anaesthesia second floor, post graduate institute of child health, Sector 30, Noida, uttar pradesh

Gautam Buddha Nagar
UTTAR PRADESH
201301
India 
Phone  9971588623  
Fax    
Email  jainmukul2004@yahoo.com  
 
Source of Monetary or Material Support  
NIL 
 
Primary Sponsor  
Name  Post graduate institute of child health 
Address  Department of paediatric anaesthesia, second floor, Post graduate institute of child health, Sector 75, Noida, uttar pradesh 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Shambhavi Sharma  Post graduate institute of child health  Department of paediatric anaesthesia OT complex, second floor postgraduate institute of child health, sector 75, noida, Uttar pradesh
Gautam Buddha Nagar
UTTAR PRADESH 
9606322036

drshambhavi2020@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutiona lethics committee   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: Q10-Q18||Congenital malformations of eye, ear, face and neck, (2) ICD-10 Condition: Q20-Q28||Congenital malformations of the circulatory system, (3) ICD-10 Condition: Q60-Q64||Congenital malformations of the urinary system, (4) ICD-10 Condition: Q30-Q34||Congenital malformations of the respiratory system, (5) ICD-10 Condition: Q65-Q79||Congenital malformations and deformations of the musculoskeletal system, (6) ICD-10 Condition: J90-J94||Other diseases of the pleura, (7) ICD-10 Condition: I70-I79||Diseases of arteries, arterioles and capillaries, (8) ICD-10 Condition: N40-N53||Diseases of male genital organs,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Erector spinae plane block with adjuvant injection butorphanol   In group B - drug will be given 0.125% bupivacaine 0.5ml/kg with adjuvant injection butorphanol 15mcg/kg.  
Intervention  Erector spinae plane block with adjuvant injection dexmedetomidine   Erector spinae plane block is given ultrasound guided, in group A-drug will be given 0.125% bupivacaine 0.5ml/kg with adjuvant injection dexmedetomidine 0.5 mcg/kg.  
 
Inclusion Criteria  
Age From  1.00 Year(s)
Age To  18.00 Year(s)
Gender  Both 
Details  1. Age: 1 year - 18 years
2. ASA I and II patients of either sex
3. Elective thoracic and abdominal surgery.
 
 
ExclusionCriteria 
Details  1. Evidence of coagulopathy or thrombocytopenia
2. History of bleeding or clotting disorders
3. Local infection
4. Allergy to drugs used in study
5. Intellectual disability
6. Chronic pain disorder
7. On chemotherapy
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded 
Primary Outcome  
Outcome  TimePoints 
duration of analgesia i.e. time of block placement to the time of administration of first rescue analgesia  upto 24 HOURS 
 
Secondary Outcome  
Outcome  TimePoints 
1. Pain score at predefined time points following surgery for upto 24 hours

 
POSTOPERATIVELY - ON ARRIVAL,
at 15 minutes, 30 minutes, 60 minutes, 90 minutes and 120 minutes, 4 hourly up to 24 hours 
haemodynamic stability  intraoperatively - every 15mins
post operatively - at 15mins, 30 ,60,90,120 minutes, 4hourly upto 24 hours 
 
Target Sample Size   Total Sample Size="52"
Sample Size from India="52" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   01/11/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - YES
  1. What data in particular will be shared?
    Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).

  2. What additional supporting information will be shared?
    Response -  Study Protocol
    Response -  Statistical Analysis Plan
    Response - Informed Consent Form
    Response - Clinical Study Report

  3. Who will be able to view these files?
    Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.

  4. For what types of analyses will this data be available?
    Response - For individual participant data meta-analysis.

  5. By what mechanism will data be made available?
    Response - Proposals should be directed to [jainmukul2004@yahoo.com].

  6. For how long will this data be available start date provided 01-08-2026 and end date provided 01-08-2029?
    Response - Beginning 9 months and ending 36 months following article publication.

  7. Any URL or additional information regarding plan/policy for sharing IPD? 
    Additional Information - nil
Brief Summary  
Earlier beliefs held that children were incapable of feeling pain but now the paediatric pain management has advanced significantly. It is widely recognised that proper care in the paediatric intensive care unit (PICU)
and pain management are essential. Pain-related stress in the paediatric population might affect emotional and neurocognitive outcomes, as well as cause pain sensitivity in childhoodRegional analgesia is one
method of delivering analgesia without risking narcotic dependence. It has been demonstrated that, the erector spinae plane block (ESPB) can reduce pain during thoracic and abdominal procedures.    Use of a
variety of adjuvant medications in conjunction with local anaesthetics, including opioids, dexmedetomidine, clonidine, dexamethasone, and butorphanol, to increase the   duration as well as intensity of analgesia.

The present study aims to compare the effectiveness of dexmedetomidine and butorphanol in reducing post-operative pain in children having thoraco-abdominal procedures, when used as an adjuvant with isobaric
bupivacaine 0.25%, in erector spinae plane block.

HYPOTHESIS -  
•Through this study, I would hypothesize that injection dexmedetomidine is better adjuvant in ESPB than injection butorphanol as it increases the time of analgesia of the patient perioperatively.
AIMS AND OBJECTIVES - 
•The aim of this study is to compare dexmedetomidine and butorphanol as an adjuvant along with bupivacaine in ultrasound-guided erector spinae plane block for perioperative analgesia in children undergoing thoracoabdominal surgeries.
•PRIMARY OUTCOME -
1.Pain score at predefined time points following surgery for upto 24 hours.
• 
•SECONDARY OUTCOME –
1.Timing of rescue analgesia.
2.Haemodynamic stability

AIMS AND OBJECTIVES

Following approval by the Departmental Protocol Committee, Department of Paediatric Anaesthesia, and the Institutional Ethics Committee, Postgraduate Institute of Child Health (PGICH), Noida, the present study would be conducted in the institution on paediatric patients undergoing open thoracic and abdominal surgeries. It is a randomized controlled study. Informed written consent will be taken from the parents/guardians.

Inclusion Criteria:

1.     Age: 1 year - 18 years

2.     ASA I and II patients of either sex

3.     Elective thoracic and abdominal surgery (such as – decortication, chest wall abscess drainage, herniotomy, exploratory laparotomy etc.)

Exclusion Criteria

1.     Evidence of coagulopathy or thrombocytopenia

2.     History of bleeding or clotting disorders

3.     Local infection

4.     Allergy to drugs used in study

5.     Intellectual disability 

6.     Chronic pain disorder

7.     On chemotherapy


METHODOLOGY

All children would be kept nil per oral before surgery as per standard ASA guidelines. The intravenous cannula would be secured in the ward before the patient is shifted to the operating room on the
 morning of surgery. Premedicate the child with intravenous midazolam 0.1 mg/kg, glycopyrrolate 4mcg/kg, ketamine 0.5 mg/kg. Transfer to the     operating room, electrocardiography, non-invasive
 blood pressure, and pulse oximetry would be connected. The baseline preoperative parameters recorded. All patients will be randomized to one of two groups using computer generated random
 numbers and a 1:1 allocation ratio. The primary investigator performing the block and the investigator analysing the data will be blinded to the group allocationAfter induction, patient will be placed in
 lateral position to apply ESPB. An assistant, who will be neither involved in the study nor will be participating in the perioperative period or the postoperative follow-up, will prepare study drugs.
Group A will receive injection 0.25% bupivacaine, single shot, 0.5ml/kg with 1 mcg/kg dexmedetomidine and Group B will receive injection 0.25% bupivacaine, single shot, 0.5ml/kg with 25
 mcg/kg  butorphanol deep to the erector spinae muscle adjacent to transverse processes. After the block, the patient of either group will be monitored for oxygen saturation, tachycardia, hypertension
 and end tidal carbon dioxide every 15 minutes. If pain persists rescue analgesia in the form of Injection paracetamol 15mg/kg will be administered. The time duration and the time of the block given till
 the first dose of rescue analgesia will be notedOn arrival in the post anaesthesia care unit (PACU), oxygen saturation (SpO2), Heart rate (HR), Mean blood pressure (MBP), end tidal carbon dioxide
 (EtCO2) and age appropriate scoring will be doneFLACC scoring (<=10 years) and VAS score (>10 years) immediately after the postoperative period once the patient is awake, then at 15 minutes, at
 30 minutes, 60 minutes, 90 minutes and 120 minutes, 4 hourly up to 24 hours. Duration of analgesia, requirement of rescue analgesia usage and side effects if any will be noted.


 
Close